Indoco Remedies Ltd Stock Price Today (NSE: INDOCO)

Indoco Remedies Ltd

221.730.10 (0.05%)
Market Closed

Fundamental Score

...

Indoco Remedies Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Indoco Remedies Ltd share price today is 221.73, down 0.05% on NSE/BSE as of 7 August 2026. Indoco Remedies Ltd (INDOCO) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 2.31K (Cr). The 52-week high for INDOCO share price is 332.20 and the 52-week low is 162.19. The company has a Return on Equity (ROE) of -9.42% and a debt-to-equity ratio of 1.16.

Indoco Remedies Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
268.00
Low
216.03
Volume
3.8L
Change
-7.26%

Indoco Remedies Ltd share price chart: -7.26% return over the past month. 52-week high ₹332.20, 52-week low ₹162.19.

Indoco Remedies Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
223.78224.40221.04221.7334.17K (Cr)
224.62226.25221.00221.8368.63K (Cr)
226.90226.90222.00222.7244.97K (Cr)
221.85228.56221.00223.582.15L (Cr)
222.78225.02220.00221.7689.08K (Cr)
218.90224.78217.05219.491.20L (Cr)
222.90222.90216.03216.691.43L (Cr)
231.00235.70223.00225.053.57L (Cr)
248.00268.00225.43228.0550.50L (Cr)
245.00250.99243.98248.1480.97K (Cr)

Indoco Remedies Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
222.78228.56220.00221.73-0.47%
237.00268.00216.03219.49-7.39%
210.00261.71198.00239.22+13.91%
211.10270.00191.00209.66-0.68%
169.90227.85167.61209.49+23.30%
195.00206.09162.19164.00-15.90%
210.00246.70195.00202.28-3.68%
235.60235.60202.96217.51-7.68%
257.70262.50222.00234.60-8.96%
282.00288.00250.10256.15-9.17%
287.55317.35270.70279.15-2.92%
264.46332.20264.11291.95+10.39%

Returns & Performance

Poor

Return on Equity (ROE)

-9.42%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

0.93%

Returns generated on total capital deployed

Good

Oper. Profit Margin (5Y Avg)

12.91%

Average operating profit margin over 5 years

Dividend Yield

0.08%

Annual dividend as % of current share price

Indoco Remedies Ltd Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

58.86%

% shares held by company founders/management

Poor

FII Holding

0.94%

% shares held by foreign institutional investors

Good

DII Holding

18.15%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

38.96%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

21.89%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

8.25%

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

1.16x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

0.15x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-412.81 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Indoco Remedies Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of INDOCO across key market metrics for learning purposes.

Positive Indicators

4 factors identified

Robust Profit Growth (38.96%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (21.89%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Balanced Promoter Holding (58.86%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

5 factors identified

Below-Average Return on Equity (-9.42%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (0.93%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Elevated Debt Levels (D/E: 1.16)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.

Weak Interest Coverage (0.15x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Negative Free Cash Flow (₹-412.81 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Indoco Remedies Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Indoco Remedies Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
26.9/100
222
₹2309.94
-9.42%
Poor
0.93%
Poor
1.2
Average
8.25%
Good
0.08%
66.4/100
1991
₹468821.49
37.7
Average
15.95%
Good
20.53%
Excellent
0.1
Excellent
16.75%
Excellent
11.78%
Good
0.82%
56.3/100
8056
₹193163.97
73.6
Average
16.53%
Good
21.96%
Excellent
0.0
Excellent
5.71%
Good
8.67%
Good
0.41%
51.4/100
5123
₹169902.02
77.5
Average
27.43%
Excellent
15.19%
Good
1.8
Average
12.07%
Good
11.80%
Good
0.76%
Cipla Ltd...
CIPLA500087
40.2/100
1473
₹116131.81
30.5
Average
11.60%
Average
15.49%
Good
0.0
Excellent
9.94%
Good
8.01%
Good
0.90%
74.1/100
1078
₹115375.77
21.3
Average
21.25%
Excellent
21.14%
Excellent
0.5
Excellent
18.77%
Excellent
12.45%
Good
0.09%
Lupin Ltd...
LUPIN500257
83.4/100
2415
₹113976.53
20.0
Average
28.68%
Excellent
29.93%
Excellent
0.3
Excellent
37.02%
Excellent
13.02%
Good
0.72%
61.5/100
2470
₹105053.91
52.3
Average
13.12%
Average
13.50%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%
41/100
1148
₹102660.46
25.6
Average
11.22%
Average
13.04%
Average
0.2
Excellent
15.44%
Excellent
12.09%
Good
0.65%
24.6/100
1580
₹90035.87
25.4
Average
10.06%
Average
12.80%
Average
0.2
Excellent
0.80%
Average
6.32%
Good
0.26%
34.1/100
1816
₹84016.75
93.9
Average
18.30%
Good
17.76%
Good
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%

Indoco Remedies Ltd PE Ratio History

Historical price-to-earnings ratio for INDOCO — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202410.51₹332.2031.6x
FY 202315.42₹395.2025.6x
FY 202216.80₹406.6524.2x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Indoco Remedies Ltd Dividend History

Annual cash dividends paid by INDOCO — dividend yield 0.08%

Financial YearDividends Paid (₹ Cr)
FY 202513.90 Cr
FY 202420.71 Cr
FY 202320.72 Cr
FY 202213.79 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Indoco Remedies Ltd Quarterly Performance

Latest quarterly metrics for INDOCO — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

21.89%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

38.96%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

8.25%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Indoco Remedies Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for INDOCO — calculated from daily price history

23RSI 14
Oversold — RSI 23

Selling pressure is heavy — potential reversal zone.

SMA 50
230
▼ Price below SMA 50 — Short-term bearish
SMA 200
230
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
327K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Indoco Remedies Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Indoco Remedies Ltd (INDOCO) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Indoco Remedies Ltd

About INDOCO (Indoco Remedies Ltd)

Indoco Remedies Ltd is a fully integrated, research-oriented pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of finished pharmaceuti...cal dosages. With a strong emphasis on innovation and quality, Indoco has built a reputation for delivering effective and affordable healthcare solutions across diverse therapeutic segments. Their expansive product portfolio caters to both domestic and international markets, solidifying their position as a trusted partner in the global pharmaceutical landscape. Driven by a commitment to scientific excellence and ethical business practices, Indoco continuously strives to improve patient outcomes and contribute to the advancement of healthcare worldwide, all while maintaining rigorous adherence to international regulatory standards. The company's therapeutic focus is exceptionally broad, encompassing critical areas such as pain management, diabetes care, cardiovascular health, and women's health. Indoco's product offerings include a diverse range of formulations, including tablets, capsules, injectables, and topical preparations, each developed with a meticulous attention to detail and adherence to strict quality control measures. By leveraging cutting-edge technology and a highly skilled workforce, Indoco remains at the forefront of pharmaceutical innovation, constantly seeking to develop novel and improved therapies that address unmet medical needs. The company's strategic partnerships and collaborations further enhance its capabilities and expand its reach, ensuring that its products are accessible to patients across the globe. Indoco's commitment to sustainable growth is evident in its continuous investments in research and development, manufacturing infrastructure, and human capital. The company operates state-of-the-art manufacturing facilities that are compliant with international regulatory standards, ensuring the consistent production of high-quality pharmaceutical products. Furthermore, Indoco places a strong emphasis on environmental sustainability, implementing eco-friendly practices throughout its operations. By combining its dedication to scientific advancement with a responsible and ethical approach to business, Indoco Remedies Ltd is poised to continue its trajectory of growth and contribute meaningfully to the health and well-being of communities worldwide.

Company Details

Symbol:INDOCO
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Suresh Govind Kare
Non-Executive Chairman & Whole time Director
Mr. Sundeep Vasant Bambolkar
Joint MD & Executive Director
Ms. Aditi Milind Panandikar
MD & Executive Director

Corporate Events

Recent
Ex-Dividend Date

INDOCO Share Price: Frequently Asked Questions

What is the current share price of Indoco Remedies Ltd?

Indoco Remedies Ltd (INDOCO) trades at ₹221.73 on NSE and BSE. Market cap ₹2.31K (Cr). Educational data only.

What is the P/E ratio of Indoco Remedies Ltd?

Indoco Remedies Ltd has a P/E of N/Ax vs industry average 34.89x.

What is the Bull Run score for Indoco Remedies Ltd?

Indoco Remedies Ltd has a Bull Run score of 26.9/100 based on 25+ financial parameters.

Does Indoco Remedies Ltd pay dividends?

Indoco Remedies Ltd has a dividend yield of 0.08%. Past dividends don't guarantee future payments.

What is the ROE of Indoco Remedies Ltd?

Indoco Remedies Ltd has ROE of -9.42%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Indoco Remedies Ltd?

Indoco Remedies Ltd has debt-to-equity of 1.16.

Is Indoco Remedies Ltd a good investment?

Bull Run gives Indoco Remedies Ltd a score of 26.9/100. This is not investment advice — consult a SEBI-registered advisor.